119 related articles for article (PubMed ID: 26067292)
1. Using ICR and SCID mice as animal models for smallpox to assess antiviral drug efficacy.
Titova KA; Sergeev AA; Zamedyanskaya AS; Galahova DO; Kabanov AS; Morozova AA; Bulychev LE; Sergeev AA; Glotova TI; Shishkina LN; Taranov OS; Omigov VV; Zavjalov EL; Agafonov AP; Sergeev AN
J Gen Virol; 2015 Sep; 96(9):2832-2843. PubMed ID: 26067292
[TBL] [Abstract][Full Text] [Related]
2. [THE USE OF THE MODEL MOUSE ICR--VARIOLA VIRUS FOR EVALUATION OF ANTIVIRAL DRUG EFFICACY].
Titova KA; Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Galakhova DO; Shishkina LN; Zamedyanskaya AS; Nesterov AE; Glotov AG; Taranov OS; Omigov VV; Agafonov AP; Sergeev AN
Vopr Virusol; 2016; 61(2):79-84. PubMed ID: 27451500
[TBL] [Abstract][Full Text] [Related]
3. New effective chemically synthesized anti-smallpox compound NIOCH-14.
Mazurkov OY; Kabanov AS; Shishkina LN; Sergeev AA; Skarnovich MO; Bormotov NI; Skarnovich MA; Ovchinnikova AS; Titova KA; Galahova DO; Bulychev LE; Sergeev AA; Taranov OS; Selivanov BA; Tikhonov AY; Zavjalov EL; Agafonov AP; Sergeev AN
J Gen Virol; 2016 May; 97(5):1229-1239. PubMed ID: 26861777
[TBL] [Abstract][Full Text] [Related]
4. Use of live Variola virus to determine whether CAST/EiJ mice are a suitable surrogate animal model for human smallpox.
Gallardo-Romero NF; Hutson CL; Carroll D; Kondas AV; Salzer JS; Dietz-Ostergaard S; Smith S; Hudson P; Olson V; Damon I
Virus Res; 2020 Jan; 275():197772. PubMed ID: 31593747
[TBL] [Abstract][Full Text] [Related]
5. Drug Development against Smallpox: Present and Future.
Delaune D; Iseni F
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932370
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
7. The Possibility of Using the ICR Mouse as an Animal Model to Assess Antimonkeypox Drug Efficacy.
Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Pyankov OV; Bodnev SA; Galahova DO; Zamedyanskaya AS; Titova KA; Glotov AG; Taranov OS; Omigov VV; Shishkina LN; Agafonov AP; Sergeev AN
Transbound Emerg Dis; 2016 Oct; 63(5):e419-30. PubMed ID: 25597343
[TBL] [Abstract][Full Text] [Related]
8. Teaching a new mouse old tricks: Humanized mice as an infection model for Variola virus.
Hutson CL; Kondas AV; Ritter JM; Reed Z; Ostergaard SD; Morgan CN; Gallardo-Romero N; Tansey C; Mauldin MR; Salzer JS; Hughes CM; Goldsmith CS; Carroll D; Olson VA
PLoS Pathog; 2021 Sep; 17(9):e1009633. PubMed ID: 34547055
[TBL] [Abstract][Full Text] [Related]
9. Smallpox research activities: U.S. interagency collaboration, 2001.
LeDuc JW; Damon I; Relman DA; Huggins J; Jahrling PB
Emerg Infect Dis; 2002 Jul; 8(7):743-5. PubMed ID: 12095449
[No Abstract] [Full Text] [Related]
10. Estimation of Absolute Bioavailability of the Chemical Substance of the Anti-Smallpox Preparation NIOCH-14 in Mice.
Mazurkov OY; Shishkina LN; Bormotov NI; Skarnovich MO; Serova OA; Mazurkova NA; Chernonosov AA; Tikhonov AY; Selivanov BA
Bull Exp Biol Med; 2020 Dec; 170(2):207-210. PubMed ID: 33263846
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
12. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R; Korom M; Buller RM; Parker S
Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).
Mucker EM; Goff AJ; Shamblin JD; Grosenbach DW; Damon IK; Mehal JM; Holman RC; Carroll D; Gallardo N; Olson VA; Clemmons CJ; Hudson P; Hruby DE
Antimicrob Agents Chemother; 2013 Dec; 57(12):6246-53. PubMed ID: 24100494
[TBL] [Abstract][Full Text] [Related]
14. Progression of pathogenic events in cynomolgus macaques infected with variola virus.
Wahl-Jensen V; Cann JA; Rubins KH; Huggins JW; Fisher RW; Johnson AJ; de Kok-Mercado F; Larsen T; Raymond JL; Hensley LE; Jahrling PB
PLoS One; 2011; 6(10):e24832. PubMed ID: 21998632
[TBL] [Abstract][Full Text] [Related]
15. Bioterrorism. Blocking smallpox: a second defense.
Cohen J
Science; 2001 Oct; 294(5542):500. PubMed ID: 11641477
[No Abstract] [Full Text] [Related]
16. Smallpox: the old and the new.
Griffiths PD
Rev Med Virol; 2004; 14(5):273-4. PubMed ID: 15334535
[No Abstract] [Full Text] [Related]
17. Smallpox in the Post-Eradication Era.
Meyer H; Ehmann R; Smith GL
Viruses; 2020 Jan; 12(2):. PubMed ID: 31991671
[TBL] [Abstract][Full Text] [Related]
18. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.
Jahrling PB; Hensley LE; Martinez MJ; Leduc JW; Rubins KH; Relman DA; Huggins JW
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15196-200. PubMed ID: 15477589
[TBL] [Abstract][Full Text] [Related]
19. [EVALUATION OF THE HUMAN SENSITIVITY TO SMALLPOX VIRUS BY THE PRIMARY CULTURES OF THE MONOCYTE-MACROPHAGES].
Zamedyanskaya AS; Titova KA; Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Galakhova DO; Nesterov AE; Nosareva OV; Shishkina LN; Taranov OS; Omigov VV; Agafonov AP; Sergeev AN
Vopr Virusol; 2016; 61(2):69-73. PubMed ID: 27451498
[TBL] [Abstract][Full Text] [Related]
20. The development and approval of tecoviromat (TPOXX
Merchlinsky M; Albright A; Olson V; Schiltz H; Merkeley T; Hughes C; Petersen B; Challberg M
Antiviral Res; 2019 Aug; 168():168-174. PubMed ID: 31181284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
